Emergent BioSolutions Inc/ US29089Q1058 /
| 2024-04-24 9:59:38 PM | Chg. -0.11 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 2.18USD | -4.80% | 15,219 Turnover: 33,035.04 |
-Bid Size: - | -Ask Size: - | 113.8 mill.USD | - | - |
Assets
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 407.2100 | 510.2000 | 542.3000 | 644.1000 | 800.1000 | ||||||
| Intangible Assets | 119.5970 | 761.6000 | 712.9000 | 663.1000 | 604.6000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 584.8170 | 1,608.6000 | 1,641.1000 | 1,687.3000 | 1,686.9000 | ||||||
| Inventories | 142.8120 | 205.8000 | 222.5000 | 307 | 350.8000 | ||||||
| Accounts Receivable | 143.6530 | 262.5000 | 270.7000 | 230.9000 | 274.7000 | ||||||
| Cash and Cash Equivalents | 178.2920 | 112.2000 | 167.8000 | 621.3000 | 576.1000 | ||||||
| Current Assets | 485.3890 | 620.8000 | 686.2000 | 1,195.9000 | 1,272.1000 | ||||||
| Total Assets | 1,070.2060 | 2,229.4000 | 2,327.3000 | 2,883.2000 | 2,959 | ||||||
Liabilities
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 41.7510 | 80.7000 | 94.8000 | 136.1000 | 128.9000 | ||||||
| Long-term debt | 13.4570 | 784.5000 | 798.4000 | 841 | 809.4000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | 72 | 63.9000 | 53.2000 | - | ||||||
| Liabilities | 157.8610 | 1,218.5000 | 1,238.8000 | 1,436.2000 | 1,340 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | 912.3450 | 1,010.9000 | 1,088.5000 | 1,447 | 1,619 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 1,070.2060 | 2,229.4000 | 2,327.3000 | 2,883.2000 | 2,959 | ||||||
Income Statement
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 560.8730 | 782.4000 | 1,106 | 1,555.4000 | 1,792.7000 | ||||||
| Depreciation (total) | - | 25 | 58.7000 | 59.8000 | 58.5000 | ||||||
| Operating Result | 124.2850 | 89.8000 | 114.1000 | 433.8000 | 352.6000 | ||||||
| Interest Income | -4.8370 | -9.9000 | -38.4000 | -31.3000 | -34.5000 | ||||||
| Income Before Taxes | 118.6330 | 81.5000 | 77.4000 | 407.2000 | 314.4000 | ||||||
| Income Taxes | 36.0390 | 18.8000 | 22.9000 | 102.1000 | 83.5000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 82.5940 | 62.7000 | 54.5000 | 305.1000 | 230.9000 | ||||||
Per Share
Cash Flow
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 208.1390 | 41.8000 | 188 | 536 | 321.1000 | ||||||
| Cash Flow from Investing Activities | -249.9320 | -897.2000 | -96.9000 | -151 | -225 | ||||||
| Cash Flow from Financing | -51.4010 | 788.7000 | -35.9000 | 69.5000 | -141 | ||||||
| Decrease / Increase in Cash | -93.2210 | -66.9000 | 55.6000 | 453.5000 | -45.2000 | ||||||
| Employees | 1,256 | 1,705 | 1,834 | 2,200 | - | ||||||
